1. Chow V, Wilkinson B, LaBadie R, Ni G, and Zwillich S (2008a) Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of oral methotrexate in rheumatoid arthritis subjects (Abstract). Clin Pharmacol Ther 83 (Suppl 1):PI-82.
2. Chow V, Ni G, LaBadie R, and Chan G (2008b) An open label study to estimate the effect of fluconazole on the pharmacokinetics of CP-690,550 in healthy adult subjects (Abstract). Clin Pharmacol Ther 83 (Suppl 36):PI-93.
3. Janus kinases in immune cell signaling
4. Gupta P Harness J Buonanno M Krishnaswami S Chapel S (2011a) Population pharmacokinetics of tasocitinib (CP-690,550) in patients with moderate to severe plaque psoriasis (Abstract). J Am Academy Dermatology 64 (Suppl 1): AB163.
5. A phase 1 study to estimate the absolute oral bioavailability of tofacitinib (CP-690,550) in healthy subjects (Abstract 1122902);Gupta;J Clin Pharmacol,2001